If you ask me right now - we have no robust evidence for JAKi, so the answer is targeting IL-6. Clearly we need more data on both, in both the newly-diagnosed and the refractory established PMR settings, especially given how common these diseases are (and how unacceptable the standard of care, in the form of long-term steroids, should be).
Plausibly, both might end up being options in the future though! I don't think we can presume they will work equally as well, that is something for us to work through but is reliant on the appropriate studies, good outcome measures, and a recognition of the damage that PMR causes.
Thanks for your comment!
If you ask me right now - we have no robust evidence for JAKi, so the answer is targeting IL-6. Clearly we need more data on both, in both the newly-diagnosed and the refractory established PMR settings, especially given how common these diseases are (and how unacceptable the standard of care, in the form of long-term steroids, should be).
Plausibly, both might end up being options in the future though! I don't think we can presume they will work equally as well, that is something for us to work through but is reliant on the appropriate studies, good outcome measures, and a recognition of the damage that PMR causes.